4//SEC Filing
Benton Andrew 4
Accession 0001192482-21-000616
CIK 0001716947other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 6:10 PM ET
Size
6.4 KB
Accession
0001192482-21-000616
Insider Transaction Report
Form 4
Benton Andrew
Director
Transactions
- Award
Stock Option
2021-06-30+65,850→ 65,850 totalExercise: $3.35Exp: 2030-01-23→ Common Stock (65,850 underlying)
Footnotes (2)
- [F1]On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.
- [F2]The option vests over three years with 1/3 of the total number of shares subject to the option vesting on the first anniversary of the date of grant and 1/36th of the total number of shares subject to the option vesting monthly thereafter, until fully vested on 01/24/2023.
Documents
Issuer
Ensysce Biosciences, Inc.
CIK 0001716947
Entity typeother
Related Parties
1- filerCIK 0001867975
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 6:10 PM ET
- Size
- 6.4 KB